O	0	10	Regulation	Regulation	NN	B-NP
O	11	13	of	of	IN	B-PP
O	14	17	the	the	DT	B-NP
O	18	26	resident	resident	JJ	I-NP
B-Cellular_component	27	38	chromosomal	chromosomal	JJ	I-NP
O	39	43	copy	copy	NN	I-NP
O	44	46	of	of	IN	B-PP
O	47	48	c	c	NN	B-NP
O	48	49	-	-	HYPH	O
O	49	52	myc	myc	NN	B-NP
O	53	55	by	by	IN	B-PP
O	56	57	c	c	NN	B-NP
O	57	58	-	-	HYPH	I-NP
O	58	61	Myb	Myb	NN	I-NP
O	62	64	is	be	VBZ	B-VP
O	65	73	involved	involve	VBN	I-VP
O	74	76	in	in	IN	B-PP
B-Cell	77	84	myeloid	myeloid	JJ	B-NP
O	85	99	leukemogenesis	leukemogenesis	NN	I-NP
O	99	100	.	.	.	O

O	102	103	c	c	SYM	O
O	103	104	-	-	:	O
O	104	107	myb	myb	NN	B-NP
O	108	110	is	be	VBZ	B-VP
O	111	112	a	a	DT	B-NP
O	113	121	frequent	frequent	JJ	I-NP
O	122	128	target	target	NN	I-NP
O	129	131	of	of	IN	B-PP
O	132	142	retroviral	retroviral	JJ	B-NP
O	143	154	insertional	insertional	JJ	I-NP
O	155	166	mutagenesis	mutagenesis	NN	I-NP
O	167	169	in	in	IN	B-PP
O	170	176	murine	murine	JJ	B-NP
O	177	185	leukemia	leukemia	NN	I-NP
O	186	191	virus	virus	NN	I-NP
O	191	192	-	-	HYPH	O
O	192	199	induced	induce	VBN	B-NP
B-Cancer	200	207	myeloid	myeloid	JJ	I-NP
I-Cancer	208	216	leukemia	leukemia	NN	I-NP
O	216	217	.	.	.	O

O	218	227	Induction	Induction	NN	B-NP
O	228	230	of	of	IN	B-PP
O	231	234	the	the	DT	B-NP
O	235	247	leukemogenic	leukemogenic	JJ	I-NP
O	248	257	phenotype	phenotype	NN	I-NP
O	258	260	is	be	VBZ	B-VP
O	261	270	generally	generally	RB	I-VP
O	271	281	associated	associate	VBN	I-VP
O	282	286	with	with	IN	B-PP
O	287	300	inappropriate	inappropriate	JJ	B-NP
O	301	311	expression	expression	NN	I-NP
O	312	314	of	of	IN	B-PP
O	315	319	this	this	DT	B-NP
O	320	335	transcriptional	transcriptional	JJ	I-NP
O	336	345	regulator	regulator	NN	I-NP
O	345	346	.	.	.	O

O	347	354	Despite	Despite	IN	B-PP
O	355	364	intensive	intensive	JJ	B-NP
O	365	379	investigations	investigation	NNS	I-NP
O	379	380	,	,	,	O
O	381	384	the	the	DT	B-NP
O	385	391	target	target	NN	I-NP
O	392	397	genes	gene	NNS	I-NP
O	398	400	of	of	IN	B-PP
O	401	402	c	c	NN	B-NP
O	402	403	-	-	HYPH	B-NP
O	403	406	myb	myb	NN	I-NP
O	407	411	that	that	WDT	B-NP
O	412	415	are	be	VBP	B-VP
O	416	428	specifically	specifically	RB	I-VP
O	429	437	involved	involve	VBN	I-VP
O	438	440	in	in	IN	B-PP
O	441	452	development	development	NN	B-NP
O	453	455	of	of	IN	B-PP
O	456	461	these	these	DT	B-NP
B-Cell	462	469	myeloid	myeloid	JJ	I-NP
O	470	477	lineage	lineage	NN	I-NP
B-Cancer	478	487	neoplasms	neoplasm	NNS	I-NP
O	488	491	are	be	VBP	B-VP
O	492	497	still	still	RB	B-ADVP
O	498	505	unknown	unknown	JJ	B-ADJP
O	505	506	.	.	.	O

O	507	509	In	In	FW	B-NP
O	510	515	vitro	vitro	FW	I-NP
O	516	522	assays	assay	NNS	I-NP
O	523	527	have	have	VBP	B-VP
O	528	537	indicated	indicate	VBN	I-VP
O	538	542	that	that	IN	B-SBAR
O	543	544	c	c	NN	B-NP
O	544	545	-	-	HYPH	O
O	545	548	myc	myc	NN	B-NP
O	549	552	may	may	MD	B-VP
O	553	555	be	be	VB	I-VP
O	556	557	a	a	DT	B-NP
O	558	564	target	target	NN	I-NP
O	565	569	gene	gene	NN	I-NP
O	570	572	of	of	IN	B-PP
O	573	574	c	c	NN	B-NP
O	574	575	-	-	HYPH	I-NP
O	575	578	Myb	Myb	NN	I-NP
O	578	579	;	;	:	O
O	580	587	however	however	RB	B-ADVP
O	587	588	,	,	,	O
O	589	599	regulation	regulation	NN	B-NP
O	600	602	of	of	IN	B-PP
O	603	606	the	the	DT	B-NP
O	607	615	resident	resident	JJ	I-NP
B-Cellular_component	616	627	chromosomal	chromosomal	JJ	I-NP
O	628	632	gene	gene	NN	I-NP
O	633	636	has	have	VBZ	B-VP
O	637	640	not	not	RB	I-VP
O	641	644	yet	yet	RB	I-VP
O	645	649	been	be	VBN	I-VP
O	650	662	demonstrated	demonstrate	VBN	I-VP
O	662	663	.	.	.	O

O	664	666	To	To	TO	B-VP
O	667	674	address	address	VB	I-VP
O	675	679	this	this	DT	B-NP
O	680	688	question	question	NN	I-NP
O	689	696	further	further	RBR	B-ADVP
O	696	697	,	,	,	O
O	698	700	we	we	PRP	B-NP
O	701	709	analyzed	analyze	VBD	B-VP
O	710	713	the	the	DT	B-NP
O	714	724	expression	expression	NN	I-NP
O	725	727	of	of	IN	B-PP
O	728	729	c	c	NN	B-NP
O	729	730	-	-	HYPH	O
O	730	733	myc	myc	NN	B-NP
O	734	736	in	in	IN	B-PP
O	737	738	a	a	DT	B-NP
B-Cell	739	751	myeloblastic	myeloblastic	JJ	I-NP
I-Cell	752	756	cell	cell	NN	I-NP
I-Cell	757	761	line	line	NN	I-NP
O	761	762	,	,	,	O
B-Cell	763	765	M1	M1	NN	B-NP
O	765	766	,	,	,	O
O	767	777	expressing	express	VBG	B-VP
O	778	779	a	a	DT	B-NP
O	780	793	conditionally	conditionally	RB	I-NP
O	794	800	active	active	JJ	I-NP
O	801	802	c	c	NN	I-NP
O	802	803	-	-	HYPH	B-NP
O	803	806	Myb	Myb	NN	I-NP
O	806	807	-	-	HYPH	I-NP
O	807	815	estrogen	estrogen	NN	I-NP
O	816	824	receptor	receptor	NN	I-NP
O	825	831	fusion	fusion	NN	I-NP
O	832	839	protein	protein	NN	I-NP
O	840	841	(	(	(	O
O	841	846	MybER	MybER	NN	B-NP
O	846	847	)	)	)	O
O	847	848	.	.	.	O

O	849	859	Activation	Activation	NN	B-NP
O	860	862	of	of	IN	B-PP
O	863	868	MybER	MybER	NN	B-NP
O	869	873	both	both	DT	B-NP
O	874	883	prevented	prevent	VBD	B-VP
O	884	887	the	the	DT	B-NP
O	888	894	growth	growth	NN	I-NP
O	895	901	arrest	arrest	NN	I-NP
O	902	909	induced	induce	VBN	B-VP
O	910	912	by	by	IN	B-PP
O	913	924	interleukin	interleukin	NN	B-NP
O	924	925	-	-	HYPH	O
O	925	926	6	6	CD	B-NP
O	927	928	(	(	(	O
O	928	930	IL	IL	NN	B-NP
O	930	931	-	-	HYPH	B-NP
O	931	932	6	6	CD	I-NP
O	932	933	)	)	)	O
O	934	937	and	and	CC	O
O	938	945	rapidly	rapidly	RB	B-VP
O	946	954	restored	restore	VBD	I-VP
O	955	956	c	c	NN	B-NP
O	956	957	-	-	HYPH	O
O	957	960	myc	myc	NN	B-NP
O	961	971	expression	expression	NN	I-NP
O	972	974	in	in	IN	B-PP
O	975	981	nearly	nearly	RB	B-NP
O	982	990	terminal	terminal	JJ	I-NP
O	991	1005	differentiated	differentiate	VBN	I-NP
B-Cell	1006	1011	cells	cell	NNS	I-NP
O	1012	1016	that	that	WDT	B-NP
O	1017	1020	had	have	VBD	B-VP
O	1021	1025	been	be	VBN	I-VP
O	1026	1033	exposed	expose	VBN	I-VP
O	1034	1036	to	to	TO	B-PP
O	1037	1039	IL	IL	NN	B-NP
O	1039	1040	-	-	HYPH	O
O	1040	1041	6	6	CD	B-NP
O	1042	1045	for	for	IN	B-PP
O	1046	1047	3	3	CD	B-NP
O	1048	1052	days	day	NNS	I-NP
O	1052	1053	.	.	.	O

O	1054	1065	Restoration	Restoration	NN	B-NP
O	1066	1074	occurred	occur	VBD	B-VP
O	1075	1077	in	in	IN	B-PP
O	1078	1081	the	the	DT	B-NP
O	1082	1090	presence	presence	NN	I-NP
O	1091	1093	of	of	IN	B-PP
O	1094	1095	a	a	DT	B-NP
O	1096	1103	protein	protein	NN	I-NP
O	1104	1113	synthesis	synthesis	NN	I-NP
O	1114	1123	inhibitor	inhibitor	NN	I-NP
O	1124	1127	but	but	CC	B-PP
O	1128	1131	not	not	RB	B-PP
O	1132	1137	after	after	IN	I-PP
O	1138	1139	a	a	DT	B-NP
O	1140	1155	transcriptional	transcriptional	JJ	I-NP
O	1156	1161	block	block	NN	I-NP
O	1161	1162	,	,	,	O
O	1163	1173	indicating	indicate	VBG	B-VP
O	1174	1178	that	that	IN	B-SBAR
O	1179	1180	c	c	NN	B-VP
O	1180	1181	-	-	HYPH	O
O	1181	1184	myc	myc	NN	B-NP
O	1185	1187	is	be	VBZ	B-VP
O	1188	1189	a	a	DT	B-NP
O	1190	1196	direct	direct	JJ	I-NP
O	1196	1197	,	,	,	I-NP
O	1198	1215	transcriptionally	transcriptionally	RB	I-NP
O	1216	1225	regulated	regulate	VBN	I-NP
O	1226	1232	target	target	NN	I-NP
O	1233	1235	of	of	IN	B-PP
O	1236	1237	c	c	NN	B-NP
O	1237	1238	-	-	HYPH	I-NP
O	1238	1241	Myb	Myb	NN	I-NP
O	1241	1242	.	.	.	O

O	1243	1244	c	c	SYM	O
O	1244	1245	-	-	:	O
O	1245	1248	myc	myc	NN	B-NP
O	1249	1251	is	be	VBZ	B-VP
O	1252	1253	a	a	DT	B-NP
O	1254	1259	major	major	JJ	I-NP
O	1260	1266	target	target	NN	I-NP
O	1267	1271	that	that	WDT	B-NP
O	1272	1282	transduces	transduce	VBZ	B-VP
O	1283	1286	Myb	Myb	NN	B-NP
O	1286	1287	'	'	''	I-NP
O	1287	1288	s	s	JJ	I-NP
O	1289	1302	proliferative	proliferative	JJ	I-NP
O	1303	1309	signal	signal	NN	I-NP
O	1309	1310	,	,	,	O
O	1311	1313	as	as	IN	B-SBAR
O	1314	1319	shown	show	VBN	B-VP
O	1320	1322	by	by	IN	B-PP
O	1323	1326	the	the	DT	B-NP
O	1327	1334	ability	ability	NN	I-NP
O	1335	1337	of	of	IN	B-PP
O	1338	1339	a	a	DT	B-NP
O	1340	1341	c	c	NN	I-NP
O	1341	1342	-	-	HYPH	B-NP
O	1342	1345	Myc	Myc	NN	I-NP
O	1345	1346	-	-	HYPH	I-NP
O	1346	1354	estrogen	estrogen	NN	I-NP
O	1355	1363	receptor	receptor	NN	I-NP
O	1364	1370	fusion	fusion	NN	I-NP
O	1371	1378	protein	protein	NN	I-NP
O	1379	1384	alone	alone	RB	B-ADVP
O	1385	1387	to	to	TO	B-VP
O	1388	1392	also	also	RB	I-VP
O	1393	1400	reverse	reverse	VB	I-VP
O	1401	1407	growth	growth	NN	B-NP
O	1408	1414	arrest	arrest	NN	I-NP
O	1415	1417	in	in	IN	B-PP
O	1418	1422	this	this	DT	B-NP
O	1423	1429	system	system	NN	I-NP
O	1429	1430	.	.	.	O

O	1431	1433	To	To	TO	B-VP
O	1434	1445	investigate	investigate	VB	I-VP
O	1446	1449	the	the	DT	B-NP
O	1450	1461	possibility	possibility	NN	I-NP
O	1462	1466	that	that	IN	B-SBAR
O	1467	1471	this	this	DT	B-NP
O	1472	1482	regulatory	regulatory	JJ	I-NP
O	1483	1493	connection	connection	NN	I-NP
O	1494	1505	contributes	contribute	VBZ	B-VP
O	1506	1508	to	to	TO	B-PP
O	1509	1512	Myb	Myb	NN	B-NP
O	1512	1513	'	'	POS	B-NP
O	1513	1514	s	s	NN	I-NP
O	1515	1527	oncogenicity	oncogenicity	NN	I-NP
O	1527	1528	,	,	,	O
O	1529	1531	we	we	PRP	B-NP
O	1532	1541	expressed	express	VBD	B-VP
O	1542	1543	a	a	DT	B-NP
O	1544	1552	dominant	dominant	JJ	I-NP
O	1553	1561	negative	negative	JJ	I-NP
O	1562	1565	Myb	Myb	NN	I-NP
O	1566	1568	in	in	IN	B-PP
O	1569	1572	the	the	DT	B-NP
B-Cell	1573	1580	myeloid	myeloid	JJ	I-NP
I-Cell	1581	1589	leukemic	leukemic	JJ	I-NP
I-Cell	1590	1594	cell	cell	NN	I-NP
I-Cell	1595	1599	line	line	NN	I-NP
I-Cell	1600	1602	RI	RI	NN	I-NP
I-Cell	1602	1603	-	-	HYPH	B-NP
I-Cell	1603	1604	4	4	CD	I-NP
I-Cell	1604	1605	-	-	HYPH	I-NP
I-Cell	1605	1607	11	11	CD	I-NP
O	1607	1608	.	.	.	O

O	1609	1611	In	In	IN	B-PP
O	1612	1616	this	this	DT	B-NP
B-Cell	1617	1621	cell	cell	NN	I-NP
I-Cell	1622	1626	line	line	NN	I-NP
O	1626	1627	,	,	,	O
O	1628	1629	c	c	NN	B-NP
O	1629	1630	-	-	HYPH	I-NP
O	1630	1633	myb	myb	NN	I-NP
O	1634	1636	is	be	VBZ	B-VP
O	1637	1646	activated	activate	VBN	I-VP
O	1647	1649	by	by	IN	B-PP
O	1650	1661	insertional	insertional	JJ	B-NP
O	1662	1673	mutagenesis	mutagenesis	NN	I-NP
O	1674	1677	and	and	CC	O
O	1678	1684	cannot	cannot	MD	B-VP
O	1685	1687	be	be	VB	I-VP
O	1688	1699	effectively	effectively	RB	B-VP
O	1700	1704	down	down	RB	I-VP
O	1705	1714	regulated	regulate	VBN	I-VP
O	1715	1717	by	by	IN	B-PP
O	1718	1726	cytokine	cytokine	NN	B-NP
O	1726	1727	.	.	.	O

O	1728	1731	Myb	Myb	NN	B-NP
O	1731	1732	'	'	POS	B-NP
O	1732	1733	s	s	NN	I-NP
O	1734	1741	ability	ability	NN	I-NP
O	1742	1744	to	to	TO	B-VP
O	1745	1753	regulate	regulate	VB	I-VP
O	1754	1755	c	c	NN	B-NP
O	1755	1756	-	-	HYPH	I-NP
O	1756	1759	myc	myc	NN	I-NP
O	1759	1760	'	'	''	I-NP
O	1760	1761	s	s	NN	I-NP
O	1762	1772	expression	expression	NN	I-NP
O	1773	1776	was	be	VBD	B-VP
O	1777	1781	also	also	RB	I-VP
O	1782	1794	demonstrated	demonstrate	VBN	I-VP
O	1795	1797	in	in	IN	B-PP
O	1798	1803	these	these	DT	B-NP
B-Cell	1804	1809	cells	cell	NNS	I-NP
O	1809	1810	,	,	,	O
O	1811	1818	showing	show	VBG	B-VP
O	1819	1820	a	a	DT	B-NP
O	1821	1830	mechanism	mechanism	NN	I-NP
O	1831	1838	through	through	IN	B-PP
O	1839	1844	which	which	WDT	B-NP
O	1845	1848	the	the	DT	B-NP
O	1849	1854	proto	proto	AFX	I-NP
O	1854	1855	-	-	HYPH	I-NP
O	1855	1863	oncogene	oncogene	NN	I-NP
O	1864	1865	c	c	NN	I-NP
O	1865	1866	-	-	HYPH	B-NP
O	1866	1869	myb	myb	NN	I-NP
O	1870	1873	can	can	MD	B-VP
O	1874	1879	exert	exert	VB	I-VP
O	1880	1883	its	its	PRP$	B-NP
O	1884	1893	oncogenic	oncogenic	JJ	I-NP
O	1894	1903	potential	potential	NN	I-NP
O	1904	1906	in	in	IN	B-PP
B-Cell	1907	1914	myeloid	myeloid	JJ	B-NP
I-Cell	1915	1922	lineage	lineage	NN	I-NP
I-Cell	1923	1936	hematopoietic	hematopoietic	JJ	I-NP
I-Cell	1937	1942	cells	cell	NNS	I-NP
O	1942	1943	.	.	.	O

